PL373275A1 - Ccr-3 receptor antagonists vii - Google Patents

Ccr-3 receptor antagonists vii

Info

Publication number
PL373275A1
PL373275A1 PL02373275A PL37327502A PL373275A1 PL 373275 A1 PL373275 A1 PL 373275A1 PL 02373275 A PL02373275 A PL 02373275A PL 37327502 A PL37327502 A PL 37327502A PL 373275 A1 PL373275 A1 PL 373275A1
Authority
PL
Poland
Prior art keywords
ccr
vii
receptor antagonists
antagonists
receptor
Prior art date
Application number
PL02373275A
Other languages
English (en)
Polish (pl)
Inventor
Bois Daisy Joe Du
Beihan Wang
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL373275A1 publication Critical patent/PL373275A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL02373275A 2001-11-30 2002-11-20 Ccr-3 receptor antagonists vii PL373275A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33481901P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PL373275A1 true PL373275A1 (en) 2005-08-22

Family

ID=23308965

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02373275A PL373275A1 (en) 2001-11-30 2002-11-20 Ccr-3 receptor antagonists vii

Country Status (16)

Country Link
US (1) US7019007B2 (OSRAM)
EP (1) EP1453804B1 (OSRAM)
JP (1) JP2005518364A (OSRAM)
KR (1) KR100579352B1 (OSRAM)
CN (1) CN1296356C (OSRAM)
AR (1) AR037586A1 (OSRAM)
AT (1) ATE370932T1 (OSRAM)
AU (1) AU2002356694A1 (OSRAM)
BR (1) BR0214611A (OSRAM)
CA (1) CA2468402A1 (OSRAM)
DE (1) DE60222015T2 (OSRAM)
ES (1) ES2291539T3 (OSRAM)
MX (1) MXPA04004980A (OSRAM)
PL (1) PL373275A1 (OSRAM)
RU (1) RU2004120065A (OSRAM)
WO (1) WO2003045917A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034257A1 (es) * 2000-06-30 2004-02-18 Du Pont Pharm Co Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
US7491737B2 (en) * 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
EP2415760A3 (en) * 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
IN2006CH00378A (en) 2003-06-30 2007-05-11 Sumitomo Chemical Co Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
US7541468B2 (en) * 2004-06-10 2009-06-02 Bristol-Myers Squibb Company Process of preparing N-ureidoalkyl-piperidines
ES2624845T3 (es) * 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953005A (en) * 1961-02-24 1964-03-18 Soc Ind Fab Antibiotiques Sifa Substituted n-phenylethyl-n-phenyl-piperazines
US5051423A (en) 1988-07-13 1991-09-24 Schering Ag Derivatized alkanolamines as cardiovascular agents
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
WO2000035451A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347770A1 (en) * 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140087A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
WO2001007427A1 (en) * 1999-07-28 2001-02-01 Daiichi Radioisotope Laboratories, Ltd. Vesamicol piperazine derivatives and drugs containing the same
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
KR20040062663A (ko) 2004-07-07
WO2003045917A2 (en) 2003-06-05
US20030153578A1 (en) 2003-08-14
CN1296356C (zh) 2007-01-24
WO2003045917A3 (en) 2003-10-09
AR037586A1 (es) 2004-11-17
ES2291539T3 (es) 2008-03-01
CN1599721A (zh) 2005-03-23
US7019007B2 (en) 2006-03-28
DE60222015T2 (de) 2008-06-05
ATE370932T1 (de) 2007-09-15
DE60222015D1 (de) 2007-10-04
RU2004120065A (ru) 2005-05-27
AU2002356694A1 (en) 2003-06-10
BR0214611A (pt) 2004-09-14
MXPA04004980A (es) 2004-08-11
KR100579352B1 (ko) 2006-05-12
JP2005518364A (ja) 2005-06-23
EP1453804A2 (en) 2004-09-08
CA2468402A1 (en) 2003-06-05
EP1453804B1 (en) 2007-08-22
WO2003045917B1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
GB2343891B (en) 4-Aroyl-piperidine CCR-3 receptor antagonists
GB9927227D0 (en) CCR-3 receptor antagonists III
EP1351933A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
IL152775A0 (en) Il-8 receptor antagonists
GB9927228D0 (en) CCR-3 receptor antagonists II
DZ3309A1 (en) Il-8 receptor antagonists
PL378753A1 (pl) Antagoniści receptora CCR-3
IL151431A0 (en) Il-8 receptor antagonists
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
EP1274415A4 (en) IL-8 RECEPTOR ANTAGONISTS
AP2002002599A0 (en) Il-8 receptor antagonists
PL362838A1 (en) Somatostatin antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
EP1265905A4 (en) IL-2 RECEPTOR ANTAGONISTS
GB0028104D0 (en) Bombesin receptor antagonists
EP1274413A4 (en) IL-8 RECEPTOR ANTAGONISTS
PL373275A1 (en) Ccr-3 receptor antagonists vii
PL370367A1 (en) Ccr-3 receptor antagonists v
EP1274428A4 (en) INTERLEUKIN-8 (IL-8) RECEPTOR ANTAGONISTS
EP1263427A4 (en) ANTAGONISTS OF THE INTERLEUKIN 8 RECEPTOR
PL370821A1 (en) N-ureido-piperidines as antagonists viii for ccr-3 receptor
EP1261329A4 (en) IL-8 RECEPTOR ANTAGONISTS
IL158063A0 (en) Crf receptor antagonists
IL151434A0 (en) Il-8 receptor antagonists
GB0110662D0 (en) Receptor

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)